DeepMed Research

ARYOGEN PHARMED CO

🇮🇷Iran

Country: 🇮🇷Iran

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study

Phase 3

Completed

Conditions: Severe Hemophilia A

Interventions: Drug: Factor VIII, recombinant human with Fc fusion (rFVIII-Fc)

First Posted Date: 2023-11-18

Last Posted Date: 2023-11-18

Lead Sponsor: AryoGen Pharmed Co.

Target Recruit Count: 50

Registration Number: NCT06137092

Locations: 🇮🇷
Dastqeib Hospital, Shiraz, Iran, Islamic Republic of
🇮🇷
Mofid Hospital, Tehran, Iran, Islamic Republic of
🇮🇷
Seyed-Al-Shohada Hospital, Isfahan, Iran, Islamic Republic of

and more 2 locations

AryoTrust® (Trastuzumab) Safety Study

Completed

Conditions: Breast Cancer

Interventions: Drug: Trastuzumab

First Posted Date: 2023-09-01

Last Posted Date: 2023-10-31

Lead Sponsor: AryoGen Pharmed Co.

Target Recruit Count: 597

Registration Number: NCT06021379

Locations: 🇮🇷
Hashemi Nezhad Hospital, Mashhad, Iran, Islamic Republic of
🇮🇷
Imam Reza Hospital, Mashhad, Iran, Islamic Republic of
🇮🇷
Shahid Fayaz-Bakhsh Hospital, Tehran, Iran, Islamic Republic of

and more 11 locations

Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors

Early Phase 1

Completed

Conditions: Hemophilia A With Inhibitor
Hemophilia B With Inhibitor

Interventions: Biological: Eptacog alfa, activated

First Posted Date: 2021-03-10

Last Posted Date: 2022-09-10

Lead Sponsor: AryoGen Pharmed Co.

Target Recruit Count: 14

Registration Number: NCT04789954

Locations: 🇮🇷
Comprehensive Hemophilia Care Center, Teheran, Iran, Islamic Republic of

Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis

Completed

Conditions: Psoriatic Arthritis
Ankylosing Spondylitis
Rheumatoid Arthritis

Interventions: Drug: Etanercept

First Posted Date: 2020-10-09

Last Posted Date: 2020-10-19

Lead Sponsor: AryoGen Pharmed Co.

Target Recruit Count: 583

Registration Number: NCT04582084

Locations: 🇮🇷
Alzahra Hospital, Isfahan, Iran, Islamic Republic of
🇮🇷
Connective Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, East Azerbaijan, Iran, Islamic Republic of
🇮🇷
Hafez Hospital, Shiraz, Fars, Iran, Islamic Republic of

and more 6 locations

Clinical Trial Comparing a Biosimilar Eptacog Alfa With Novoseven, in Patients With Hemophilia With Inhibitors

Phase 3

Completed

Conditions: Hemophilia A or B With Inhibitor

Interventions: Biological: Biosimilar eptacog alfa, activated (AryoSeven)
Biological: Eptacog alfa, activated (Novoseven)

First Posted Date: 2019-05-02

Last Posted Date: 2021-02-04

Lead Sponsor: AryoGen Pharmed Co.

Target Recruit Count: 48

Registration Number: NCT03935334

Locations: 🇹🇷
Acibadem Adana Hastanesi, Pediatrik Hematoloji-Onkoloji Bölümü, Adana, Turkey
🇮🇷
Ali Asghar Hospital, Zahedan, Iran, Islamic Republic of
🇹🇷
Hacettepe Üniversitesi Çocuk Sağlığı ve Hastalıkları Anabilim Dalı Çocuk Hematolojisi Bilim Dalı, Ankara, Turkey

and more 5 locations

Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer

Phase 3

Completed

Conditions: Malignant Neoplasm of Breast

Interventions: Drug: Trastuzumab plus docetaxel (for four 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide

First Posted Date: 2018-02-07

Last Posted Date: 2024-06-28

Lead Sponsor: AryoGen Pharmed Co.

Target Recruit Count: 108

Registration Number: NCT03425656

Locations: 🇮🇷
Javadol Aemeh Clinic, Kerman, Iran, Islamic Republic of
🇮🇷
Tohid Hospital, Sanandaj, Iran, Islamic Republic of
🇮🇷
Masood Clinic, Tehran, Iran, Islamic Republic of

and more 16 locations

Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven

Completed

Conditions: Hemophilia A With Inhibitor
Hemophilia B With Inhibitor
Glanzmann's Thrombasthenia
Factor VII Deficiency

First Posted Date: 2017-12-14

Last Posted Date: 2022-02-15

Lead Sponsor: AryoGen Pharmed Co.

Target Recruit Count: 200

Registration Number: NCT03372993

Locations: 🇮🇷
Iranian Blood Transfusion Organization (IBTO), Tehran, Iran, Islamic Republic of
🇮🇷
MAHTA (Iranian Hemophilia and Thrombophilia Association), Tehran, Iran, Islamic Republic of

Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Denosumab 60 mg (Arylia) Versus Prolia® in Improvement of Bone Mineral Densitometry (BMD) Among Osteoporotic Postmenopausal Women

Phase 3

Conditions: Osteoporosis

Interventions: Drug: Denosumab
Dietary Supplement: calcium
Dietary Supplement: vitamin D

First Posted Date: 2017-09-26

Last Posted Date: 2020-07-10

Lead Sponsor: AryoGen Pharmed Co.

Target Recruit Count: 190

Registration Number: NCT03293108

Locations: 🇮🇷
Rheumatology Center of Iran, Tehran, Iran, Islamic Republic of

Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer

Phase 3

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Bevacizumab + FOLFIRI-3

First Posted Date: 2017-09-20

Last Posted Date: 2021-01-22

Lead Sponsor: AryoGen Pharmed Co.

Target Recruit Count: 126

Registration Number: NCT03288987

Locations: 🇮🇷
Shahid Beheshti Hospital, Hamadān, Iran, Islamic Republic of
🇮🇷
Masoud Internal Clinic, Tehran, Iran, Islamic Republic of
🇮🇷
Safa najafi clinic, Tehran, Iran, Islamic Republic of

and more 19 locations

Pharmacokinetic, Safety and Tolerability Study of Altebrel in Healthy Male Subjects

Phase 1

Completed

Conditions: Phase 1
Bioequivalence

Interventions: Drug: Etanercept

First Posted Date: 2017-09-06

Last Posted Date: 2018-09-19

Lead Sponsor: AryoGen Pharmed Co.

Target Recruit Count: 34

Registration Number: NCT03273088

Locations: 🇮🇷
Orchidpharmed PK/PD site, Tehrān, Tehran, Iran, Islamic Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy